Swiss Biotech Anokion Raises $40 Million in Series B Round
September 11 2019 - 12:24PM
Dow Jones News
By Colin Kellaher
Swiss biotechnology startup Anokion SA on Wednesday said it
raised $40 million in a Series B financing at an undisclosed
valuation, bringing total equity and partner capital to more than
$160 million.
Anokion, which is developing technology for retraining white
blood cells to induce therapeutic immune tolerance, also said it
has acquired Kanyos Bio Inc., adding KAN-101, a treatment for
celiac disease, to its portfolio.
Existing investors Versant Ventures, Novartis Venture Fund and
Novo Ventures participated in a round, along with Celgene Corp.
(CELG), which formed a collaboration with Anokion in early
2017.
Anokion's lead product, ANK-780, is an antigen-specific
treatment for multiple sclerosis. The company said it expects to
have ANK-780 and KAN-101 in clinical development within the next 12
months.
Kanyos was formed in 2015 through a collaboration with Anokion
and Astellas Pharma Inc. (4503.TO), at which time Astellas made an
equity investment in the company. Anokion and Astellas mutually
ended the collaboration last year, and Kanyos has been operating as
an independent company since then.
-Brian Gormley contributed to this article.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 11, 2019 12:09 ET (16:09 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024
